How to identify and manage ‘problem’ excipients in medicines for children
Children may be exposed to potentially harmful excipients, essential components of drug formulations, through unlicensed and off-label use of adult medicines. Excipient exposure should be minimised, although a medicine containing a problem excipient may be indicated, but only after a careful risk–benefit assessment.
Source: Gustoimages / Science Photo Library
Oral liquid formulations, such as solutions and suspensions, are commonly given to young children because they are easy to swallow. However, many liquid formulations have not been studied extensively, or authorised for paediatric use. This has resulted in the widespread routine clinical use of unlicensed medicines, and the use of adult medicines outside of their licence, usually referred to as ‘off-label’ use, in children.
Excipients are essential components of drug formulations, facilitating their manufacture and storage. However, the excipients used in adult formulations may not be appropriate for paediatric patients, and therefore have the potential to lead to adverse effects.
Children may not be able to metabolise or eliminate an excipient in the same way as an adult, because of their physiological and developmental differences. Pre-term, low-birth neonates and infants are particularly vulnerable owing to the immaturity of their hepatic and renal systems for metabolism and elimination.
Manufacturers’ summaries of product characteristics (SPCs) are useful for identifying the excipients in a particular medicine. SPCs can be accessed via the electronic medicines compendium. Manufacturers’ medical information departments are also very helpful for determining the specific amounts of excipients present in formulations.
This article aims to raise awareness of ‘problem’ excipients that can cause adverse reactions in children and provide information for pharmacists and healthcare professionals to determine whether a liquid formulation is suitable.
Common ‘problem’ excipients
The potential issues associated with excipients in oral, topical and intravenous formulations are highlighted in Table 1. Please note that the list is not exhaustive and that exclusion does not indicate safety.
|Table 1: Examples of ‘problem’ excipients, their role in formulations and potential adverse effect(s)|
|Excipient||Role in formulation||Adverse effect(s)|
|Propylene glycol||Solvent||Central nervous system (CNS) effects, especially in neonates and children under four years|
|Polyoxyl castor oil||Vehicle||Severe anaphylactoid reactions|
|Polysorbate 80||Solubilising agent||E-Ferol syndrome, hypersensitivity reactions|
|Benzyl alcohol||Preservative||‘Gasping syndrome’ in neonates|
|Benzoic acid||Preservative||Jaundice in neonates,|
|Parabens (methyl-, ethyl- and propyl-hydroxybenzoates)||Preservative||Suggestion of oestrogenic activity with potential reproductive effects (with propylparaben),, hypersensitivity reactions, hyperbilirubinaemia in neonates|
|Benzalkonium chloride||Preservative||Bronchospasm from anti-asthmatic drugs,|
|Sodium metasulfites||Antioxidant||Wheezing, dyspnoea and chest tightness in asthmatic children|
|Sorbitol||Sweetener||Osmotic diarrhoea and gastrointestinal discomfort,|
|Glucose and sucrose||Sweetener||Obesity and tooth decay|
|Saccharin||Artificial sweetener||Hypersensitivity and photosensitivity reactions,|
|Aspartame||Artifical sweetener||A source of phenylalanine that should be avoided in patients with phenylketonuria ,|
|Colourants||Colouring agents||Sensitivity reactions and hyperactive behaviour in children|
The solvent propylene glycol (PG) is used in a variety of oral liquid, topical and injectable medicines. Accumulation of PG can occur in neonates and young children as they cannot adequately metabolise and eliminate the excipient,. This reduced metabolism and elimination can lead to depression of the central nervous system (CNS). Despite clinical data demonstrating that higher PG load may be safely administered to children >4 years and adults, a more cautious approach is still recommended for children under 5 years because of a lack of clinical data. Table 2 provides more detail on the European Medicines Agency (EMA) proposed safety limits for PG in children. Box 1 describes how to calculate the quantity of PG in a pharmaceutical product (in % w/v), including a worked example.
|Table 2: European Medicines Agency proposed safety limits for propylene glycol |
|Neonates up to 28 days (or 44 weeks post-menstrual age for pre-terms)||Children aged 1 month–4 years||Children aged 5–17 years|
|Safety limits (maximum daily dose)||1mg/kg||50mg/kg||500mg/kg|
Box 1: Calculating the quantity of propylene glycol (PG) in a pharmaceutical product (in % w/v), with a worked example
Some manufacturers state the amount of PG in ml/5ml of product. The concentration in % v/v can be converted to % w/v using the specific gravity of PG, which is 1.036 (i.e. 1ml weighs 1.036g).
Amiloride 5mg/5ml sugar-free oral solution (Rosemont Pharmaceuticals) contains 0.1ml PG per 5ml of solution = 2% v/v concentration. Using the specific gravity of PG, a concentration of 2% v/v corresponds to 2.07% w/v (2ml/100ml x 1.036 = 2.07g/100ml).
The dose of amiloride for a neonate is 100–200µg/kg twice daily.
Using the lowest dose, a neonate weighing 3.5kg would receive 350µg twice daily (i.e. 700µg per day).
There is 700µg in 0.7ml of the oral solution.
This neonate can therefore safely receive up to 3.5mg of PG per day.
With a PG concentration of 2.07% w/v, there is 2,070mg PG in 100ml of oral solution. In 0.7ml of oral solution, there is 14.49mg PG. This is above the proposed safety limit for this neonate.
Another solvent, ethanol, is widely used in oral liquid formulations. Use in children is associated with risk of acute intoxication with accidental overdose and chronic toxicity with long-term use. Children, especially those aged under six years, are more vulnerable to the effects of alcohol, which may include drowsiness, behavioural changes, and impaired ability to concentrate and participate in school activities. Commonly used liquid formulations containing ethanol include ranitidine, phenobarbitone, furosemide and some morphine preparations.
In January 2014, the EMA proposed the inclusion of more detailed information on alcohol content in patient information leaflets (PILs) as well as alcohol content thresholds for different age groups in a draft for the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’,. Table 3 provides more detail on EMA proposed safety thresholds for ethanol in children aged ≤12 years. Box 2 describes how to calculate the quantity of ethanol in a pharmaceutical product (in % w/v), with a worked example.
|Table 3: European Medicines Agency (EMA) proposed safety thresholds for ethanol in children ≤12 years of age |
|Children aged <6 years||Children aged 6–12 years|
|EMA proposed ethanol thresholds in paediatric population||Blood-alcohol concentration should not exceed 1mg/100ml (a dose of 6mg/kg)||Blood-alcohol concentration should not exceed 12.5mg/100ml (a dose of 75mg/kg)|
Box 2: Calculating the quantity of ethanol in a pharmaceutical product (in % w/v), with a worked example
In the UK, information on ethanol content of a medicine can be found in the patient information leaflet (PIL) or the summary of product characteristics (SPC). The concentration in % v/v can be converted to % w/v using the specific gravity of ethanol (alcohol), which is 0.789 (0.8 can be used as an approximation).
Phenobarbital Elixir BP (15mg/5ml) contains 38% v/v ethanol. Using the specific gravity of ethanol, this corresponds to a concentration of around 30.4% w/v.
The maintenance dose of phenobarbital is 2.5–4 mg/kg, once or twice a day for epilepsy in children aged 1 month–11 years. Using the lowest dose, a child aged 3 years weighing 14kg would receive 35mg daily (11.7ml of Phenobarbital Elixir).
This 3-year-old child can receive up to 84mg of ethanol per dose.
With an ethanol concentration of 30.4% w/v, there is 30.4g of ethanol in 100ml of elixir. In 11.7ml of elixir, there is 3.55g of ethanol. This is far above the proposed safety threshold.
An unlicensed 50mg/5ml alcohol-free phenobarbital suspension is available and should be prescribed and supplied in this instance.
The sugar alcohol sorbitol is commonly used as a vehicle and stabiliser in oral liquid formulations, in addition to its role as a sweetener. Preparations containing sugar alcohols are marketed as ‘sugar-free’ since they do not cause dental caries. As they are absorbed more slowly than conventional sugars, sugar alcohols are considered suitable for diabetic patients. Common adverse effects associated with sorbitol include osmotic diarrhoea and gastrointestinal discomfort,. Limited data are available on the relevant thresholds of polyols (e.g. sorbitol, mannitol) in children, although an oral dose of greater than 140mg/kg/day may result in gastrointestinal symptoms. Sorbitol is metabolised to fructose and is, therefore, unsuitable for patients with hereditary fructose intolerance. Box 3 describes how to calculate the amount of sorbitol in an oral suspension.
Box 3: Calculating the amount of sorbitol in an oral suspension
Amoxicillin 125mg/5ml oral suspension sugar-free BP (Kent Pharmaceuticals) contains 800mg sorbitol per 5ml.
A patient aged 1 year (weight 9kg) prescribed a 250mg three times daily dose will be receiving 4.8g (533.3mg/kg) of sorbitol per day.
Aspartame and saccharin are artificial sweeteners that are low-calorie or calorie-free; non-cariogenic; and, within the acceptable daily intake (ADI), considered safe for consumption by diabetic patients. ADIs for the general population are 40mg/kg/day and 5mg/kg/day for aspartame and saccharin, respectively,. They are used to increase palatability and to mask unpleasant taste. The evidence-base shows that artificial sweeteners are considered safe to consume up to the ADI in the general population, with the exception of foods for infants and young children (aged <3 years). Despite being prohibited by the European Union in foods for children aged <3 years, artificial sweeteners are present in a number of medicines licensed for these age groups including amoxicillin 125/31 sugar-free suspension BP, Epilim Syrup, Nystatin Oral Suspension BP and prednisolone 5mg soluble tablets.
Although the use of artificial colours in foods for children aged <3 years is prohibited, this law does not apply to medicines. Colouring agents are used in medicinal preparations to improve acceptability to patients, to aid identification and prevent counterfeiting. They are also used to increase the stability of light-sensitive drugs. They are not recommended to be given to children because the use of many colouring agents, mainly synthetic dyes, have been associated with hypersensitivity and other adverse reactions in these patients. Their use in paediatric preparations must be justified in terms of the necessity to colour the preparation and the selection of a particular colouring agent.
Unlicensed medicines that do not have a UK or European marketing authorisation are often categorised as specials. They are produced and distributed to meet the needs of an individual patient. A special should not be supplied when an equivalent licensed medicinal product can meet the specific needs of the patient,.
Specials are sometimes prescribed for children given the lower doses compared with the usual adult dose and the lack of licensed products for use in this population. They have not been assessed by the regulatory authority (EMA or the Medicines and Healthcare products Regulatory Agency [MHRA]) for safety, quality and efficacy in the same way as a licensed medicine. They do not have SPCs and PILs may not be readily available. Specials do not come in standard concentrations, which can lead to confusion and error, especially when doses are prescribed in millilitres rather than milligrams.
There are occasions when specials are the most appropriate option for a patient’s needs. However, pharmacists have a professional responsibility to minimise the risks for patients when using a special. Box 4 outlines key points that pharmacists and healthcare professionals should consider regarding specials.
Box 4: Key practice points for using specials
- Use a licensed product within the terms of its licence as first choice, or ‘off-label’ as second choice, before considering obtaining an unlicensed medicine or special;
- Order the same special from the same supplier to try to minimise product variation and patient or carer confusion;
- Check whether the excipients are suitable for the individual patient.
Manufacturers’ SPCs are useful for identifying the excipients in a particular medicine but amounts are rarely specified. Clear safety limits and quantitative information on problem excipients in children are needed to aid pharmacists and healthcare professionals in medicine selection for these patients. This is especially important in neonates and young children and when patients are taking multiple liquid medications. Exposure to these excipients should be minimised as much as possible, but a medicine containing a problem excipient may be indicated after a careful risk–benefit assessment.
Sara Arthur and Anna Burgess also provide the information support service to the Neonatal and Paediatric Pharmacists Group (NPPG), a Royal Pharmaceutical Society Affiliated Partner.
Reading this article counts towards your CPD
You can use the following forms to record your learning and action points from this article from Pharmaceutical Journal Publications.
Your CPD module results are stored against your account here at The Pharmaceutical Journal. You must be registered and logged into the site to do this. To review your module results, go to the ‘My Account’ tab and then ‘My CPD’.
Any training, learning or development activities that you undertake for CPD can also be recorded as evidence as part of your RPS Faculty practice-based portfolio when preparing for Faculty membership. To start your RPS Faculty journey today, access the portfolio and tools at www.rpharms.com/Faculty
If your learning was planned in advance, please click:
If your learning was spontaneous, please click:
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203121
Recommended from Pharmaceutical Press